Catherine M. Albert

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 955 citations · Full text

Phase 1/2, Surgical Oncology, Tumoral Pathology +9

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas et al. · The Lancet Oncology · 2018 · 536 citations · Full text

Tumoral Pathology, Medicine, Pathology +7

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Cécile Couchoud, Florian Bayer, Carole Ayav et al. · Kidney International · 2020 · 150 citations · Full text

Hemodialysis, Medicine, Covid-19 Pandemic +9

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Steven G. DuBois, Theodore W. Laetsch, Noah Federman et al. · Cancer · 2018 · 134 citations · Full text

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors

Jessica L. Davis, Christina M. Lockwood, Bradley A. Stohr et al. · The American Journal of Surgical Pathology · 2018 · 134 citations

Tumoral Pathology, Pediatric Brain Tumors, Variant Ntrk Fusions +11